• Explore /
  • Poster
  • / Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.

Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.

Abstract Poster

Authors

null

Elias Jabbour

The University of Texas MD Anderson Cancer Center, Houston, TX

Elias Jabbour , Nicola Gökbuget , Anjali S. Advani , Matthias Stelljes , Wendy Stock , Michaela Liedtke , Giovanni Martinelli , Susan Mary O'Brien , Tao Wang , Douglas Laird , Erik Vandendries , Alexander Neuhof , Daniel J. DeAngelo , Hagop M. Kantarjian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01564784

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7013)

DOI

10.1200/JCO.2018.36.15_suppl.7013

Abstract #

7013

Poster Bd #

73

Abstract Disclosures

Similar Posters

First Author: Hagop M. Kantarjian

First Author: Ryan Daniel Cassaday

First Author: Wendy Stock

First Author: Daniel J. DeAngelo